Auto-Injector & Multi-Dose Pen Technologies


Our internal development team has more than 30 years of experience in developing and engineering best-in-class auto-injector devices. This team specializes in creating custom designed drug delivery devices that address patient and therapeutic needs.


We combine drug development expertise with proprietary auto-injector technology to deliver medicines. With a goal of improving the patient experience, we seek to produce treatment options that best serve our patients, physicians, partners, and stakeholders. Select partners with commercially approved products in various jurisdictions, include::

  • Epinephrine Injection USP (generic equivalent to EpiPen® and EpiPen® Jr.): Teva
  • Teriparatide Injection (generic version of Forteo® and Forsteo®): Teva
  • OTREXUP® (methotrexate) injection: Otter

Inspiring New Options

Partner Auto-Injector Pipeline

Our auto-injector technology is globally validated and is used in five approved therapeutics, providing improved dose administration and treatment options, with additional products currently in development.

The content below contains information on investigational products and uses that have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of development programs and should be construed as conclusions of efficacy, safety, or future approval of any product.

[auto-iframe link=]

Are you interested in learning more about our partnerships and business development opportunities? Contact

Halozyme Auto-Injector Pipeline

[auto-iframe link=]